TamRx, a cancer immunotherapy firm, was launched jointly by BioMotiv and Rutgers University on Thursday to advance its experimental pan-TAM inhibitors candidate to clinical trial stage by 2021. The startup plans to evaluate the efficacy of its inhibitors when combined with checkpoint inhibitors as well as other immunotherapies for an assortment of cancers.
Rutgers, BioMotiv launch cancer immunotherapy company startup
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.